» Articles » PMID: 17404313

Scar-associated Macrophages Are a Major Source of Hepatic Matrix Metalloproteinase-13 and Facilitate the Resolution of Murine Hepatic Fibrosis

Overview
Journal J Immunol
Date 2007 Apr 4
PMID 17404313
Citations 225
Authors
Affiliations
Soon will be listed here.
Abstract

Both the identity and source of the rodent collagenase(s) that mediates matrix remodeling in liver fibrosis remain elusive. We have recently demonstrated an unequivocal role for scar-associated macrophages (SAMs) in the spontaneous resolution of liver fibrosis and sought to determine whether SAMs are the source of matrix metalloproteinase (MMP) 13 (collagenase 3), considered to be the primary interstitial collagenase in rodents. In this study, we demonstrate an association between MMP13 expression and the presence of SAMs in the regression of experimental liver fibrosis. mmp13 gene expression was restricted to regions of fibrosis that were rich in SAMs. Both MMP13 mRNA and protein colocalized to large phagocytes within and directly apposed to hepatic scars. Using the CD11b-DTR-transgenic mouse to deplete SAMs in a model of chronic CCl(4) injury, we found that SAM depletion resulted in a 5-fold reduction in mmp13 message (p = 0.005). Furthermore, resolution of CCl(4)-induced fibrosis was retarded in MMP13-deficient mice. Thus, SAMs selectively, during resolution of fibrosis induce and use the major collagenase MMP13 to mediate the resorption of interstitial matrix and successfully remodel the fibrotic liver.

Citing Articles

Pro-Fibrotic Macrophage Subtypes: SPP1+ Macrophages as a Key Player and Therapeutic Target in Cardiac Fibrosis?.

Uhlig M, Billig S, Wienhold J, Schumacher D Cells. 2025; 14(5).

PMID: 40072075 PMC: 11898914. DOI: 10.3390/cells14050345.


Identification of pro-fibrotic cellular subpopulations in fascia of gluteal muscle contracture using single-cell RNA sequencing.

Zhao W, Li Z, Ma S, Chen W, Wan Z, Zhu L J Transl Med. 2025; 23(1):192.

PMID: 39962491 PMC: 11834283. DOI: 10.1186/s12967-024-05889-y.


Not the end of the road for macrophage therapy in liver cirrhosis.

Maher J Nat Med. 2025; .

PMID: 39901047 DOI: 10.1038/s41591-025-03490-4.


Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trial.

Brennan P, MacMillan M, Manship T, Moroni F, Glover A, Troland D Nat Med. 2025; .

PMID: 39794616 DOI: 10.1038/s41591-024-03406-8.


Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies.

Di X, Li Y, Wei J, Li T, Liao B Adv Sci (Weinh). 2024; 12(3):e2410416.

PMID: 39665319 PMC: 11744640. DOI: 10.1002/advs.202410416.